Dasatinib
Endometrial Serous Adenocarcinoma
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Endometrial Serous Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin National Cancer Institute (NCI) | Phase 3 | BB |
Temsirolimus National Cancer Institute (NCI) | Phase 2 | B |
Cediranib National Cancer Institute (NCI) | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Doxycycline Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 | CCC |
View all 22 →
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →